
Goutham Sunny: Key Findings from BRAF V600E in MSI-H mCRC
Goutham Sunny, Former Resident Doctor at The Gujarat Cancer and Research Institute, shared a post on X:
“BRAF V600E in MSI-H mCRC: No OS Impact Overall, But Higher 1L Resistance
Retrospective cohort (n=909) of MSI-H/dMMR mCRC patients treated with ICIs (2014–2023), evaluating prognostic impact of BRAF V600E mutation.
Key Findings:
– BRAF mutation (BRAFm) present in 38% (345/909)
– Across all lines of ICI therapy:
• No difference in PFS (25.0 vs 41.5 mo, adjHR 0.97, p=0.8)
• No difference in OS (55.1 mo vs not reached, adjHR 0.98, p=0.9)
First-Line ICI Subset:
– Higher secondary resistance in BRAFm: 20% vs 11% (p=0.02)
– Among those with disease control ≥6 mo:
• BRAFm had shorter PFS (adjHR 2.09, p=0.03)
• and shorter OS (adjHR 2.80, p=0.019)
– Dual ICI (anti-PD1 + anti-CTLA4) eliminated this negative prognostic impact
Clinical Implication for Oncologists:
– In MSI-H/dMMR mCRC, BRAF V600E is not universally prognostic on ICI
– But in 1L setting, BRAFm pts face higher secondary resistance and worse post-progression outcomes
– Dual checkpoint blockade may overcome this disadvantage—supports combination ICI use upfront in BRAFm MSI-H mCRC”
Title: Prognostic impact of the BRAF V600E mutation in patients with MSI-high metastatic colorectal cancer treated with immune checkpoint inhibitors
Authors: Claire Gallois, Margherita Ambrosini, Sara Lonardi, Emily Alouani, Rosine Guimbaud, Michael J. Overman, Frank Sinicrope, Thibault Mazard, Marie Decraecker, Javier Ros, Elena Elez, Simon Pernot, Chiara Cremolini, Alice Boilève, Pauline Parent, Priya Jayachandran, Marie Dutherage, Mathilde Mercier, Clémence Flecchia, Marwan Fakih, Francesco Sclafani, Filippo Pietrantonio, Julien Taieb, David Tougeron
You can read the Full Article in the European Journal of Cancer.
More posts featuring Goutham Sunny on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023